Impact of Obesity on Health-Related Quality of Life, Sleep, and Work – a Multinational Survey
Author(s)
Khare S1, Redig J2, Higgins V3, Leith A4, Mortimer A3, Tahbaz A5, Artime E6
1Eli Lilly and Company, Woking, SRY, UK, 2Eli Lilly and Company, Stockholm, Sweden, 3Adelphi Real World, Bollington, UK, 4Adelphi Real World, Bollington, CHE, UK, 5Eli Lilly and Company, Bracknell, UK, 6Eli Lilly and Company, ALCOBENDAS - MADRID , M, Spain
Presentation Documents
OBJECTIVES: To describe the impact of obesity on health-related quality of life (HRQoL), sleep and work delineated by BMI and the presence of comorbidities.
METHODS: Data were drawn from the Adelphi Obesity Disease Specific Programme™, a cross-sectional survey of physicians and the people with obesity (PwO) whom they manage on a weight management programme or using anti-obesity medications, conducted in Brazil, Canada, China, Japan, Saudi Arabia and the United Arab Emirates from April–December 2022. Physicians reported demographics and clinical characteristics for their consecutive 3 to 8 qualifying PwO. PwO were then invited to complete a questionnaire containing SF-36v2.0 Health Survey (scores range from 0 - 100, with higher scores indicating better HRQoL), Jenkins Sleep Evaluation Questionnaire (JSEQ; where 0 indicated no sleep problems to 20 indicating most sleep problems) and Work Productivity and Activity Impairment Questionnaire (higher scores indicating greater impairment and less productivity). PwO who completed all 3 patient-reported outcome measures were then grouped by current BMI (kg/m2) i) <30/<28 in China/<25 in Japan [B0] and ii) ≥30/≥28 in China/≥25 in Japan [B1], and by presence of comorbidities i) none [C0] and ii) ≥1 [C1]. Analyses were descriptive.
RESULTS: Of a total 1,434 PwO (n/%: 243/17% were B0 and 1191/83% B1; 262/18% were C0 and 1172/82% C1), mean±SD age was 40.5±12.5 years, 57% female, 71% employed. Mean±SD BMI at diagnosis was 34.2±8.4, current 32.2±7.6. Mean±SD SF-36v2.0 component summary scores: physical, 50.0±7.9 (B0), 46.8±8.4 (B1); 50.3±7.3 (C0), 46.7±8.5 (C1); mental, 44.9±9.1 (B0), 44.4±10.1 (B1); 46.4±8.7 (C0), 44.1±10.1 (C1). Mean±SD JSEQ scores: 4.9±4.3 (B0), 5.0±4.1 (B1); 4.3±3.9 (C0), 5.2±4.2 (C1)). Mean±SD overall work impairment scores: 61.5%±11.1 (B0), 65.7%±12.2 (B1); 61.7%±11.4 (C0), 65.8%±12.2 (C1).
CONCLUSIONS: Our results suggest obesity and comorbidity presence have an impact on HRQoL and work. Future awareness of this when managing PwO could help optimise outcomes.
Conference/Value in Health Info
Value in Health, Volume 26, Issue 11, S2 (December 2023)
Code
PCR4
Topic
Economic Evaluation, Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes, Work & Home Productivity - Indirect Costs
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas